Sustained Viral Response and Hematological Adverse Events in Children With Chronic Hepatitis C

Over the past decades, data from randomized controlled trials have confirmed the use of pegylated interferon alpha (peg-IFNα) plus ribavirin (RBV), as the mainstay of HCV therapy in adults (1). In children aged 3 years and older, the Food and Drug administration in the United States did not approve the use of this combination therapy until December 2008, and for children in Europe, approval from the European Medicines Agency came a year later in September 2009.